(ORGO) Organogenesis Holdings - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 288m USD | Total Return: -41.9% in 12m

Wound Care, Surgical, Sports Medicine, Regenerative Medicine
Total Rating 45
Safety 73
Buy Signal -0.99
Drug Manufacturers - Specialty & Generic
Industry Rotation: -0.8
Market Cap: 288M
Avg Turnover: 1.60M USD
ATR: 6.63%
Peers RS (IBD): 1.0
Risk 5d forecast
Volatility79.6%
Rel. Tail Risk-19.2%
Reward TTM
Sharpe Ratio-0.19
Alpha-72.07
Character TTM
Beta1.168
Beta Downside1.390
Drawdowns 3y
Max DD65.75%
CAGR/Max DD0.01
EPS (Earnings per Share) EPS (Earnings per Share) of ORGO over the last years for every Quarter: "2021-03": 0.07, "2021-06": 0.15, "2021-09": 0.1, "2021-12": 0.39, "2022-03": 0.0091, "2022-06": 0.07, "2022-09": 0.0369, "2022-12": 0.06, "2023-03": -0.02, "2023-06": 0.04, "2023-09": 0.02, "2023-12": -0.0043, "2024-03": -0.02, "2024-06": 0.04, "2024-09": 0.0966, "2024-12": 0.0662, "2025-03": -0.17, "2025-06": -0.1, "2025-09": 0.1227, "2025-12": 0.4001, "2026-03": 0,
EPS CAGR: -8.58%
EPS Trend: 15.7%
Last SUE: 0.84
Qual. Beats: 2
Revenue Revenue of ORGO over the last years for every Quarter: 2021-03: 102.552, 2021-06: 123.196, 2021-09: 113.753, 2021-12: 128.558, 2022-03: 97.117, 2022-06: 121.401, 2022-09: 116.859, 2022-12: 115.516, 2023-03: 107.642, 2023-06: 117.316, 2023-09: 108.531, 2023-12: 99.651, 2024-03: 109.976, 2024-06: 130.234, 2024-09: 115.177, 2024-12: 126.656, 2025-03: 86.693, 2025-06: 100.779, 2025-09: 150.864, 2025-12: 225.607, 2026-03: null,
Rev. CAGR: 25.20%
Rev. Trend: 40.8%
Last SUE: 4.00
Qual. Beats: 2

Warnings

Volatile

Tailwinds

Pead

Description: ORGO Organogenesis Holdings

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development and commercialization of solutions for advanced wound care, surgical, and sports medicine markets. Its portfolio includes bioengineered skin substitutes, placental allografts, and antimicrobial barriers designed to treat chronic wounds, such as diabetic foot ulcers and venous leg ulcers, as well as acute surgical wounds. The company operates within the biotechnology sector, where high research and development costs are standard for maintaining a pipeline of FDA-regulated biological products.

The company’s business model relies on a direct sales force and independent agencies to distribute products to hospitals, ambulatory surgery centers, and physician offices. Beyond its current commercial offerings, Organogenesis is expanding into the orthopedics market with late-stage clinical trials for treatments targeting knee osteoarthritis. This expansion highlights a trend in the regenerative medicine industry toward diversifying tissue-engineered products into broader musculoskeletal applications.

To better understand how these clinical developments might impact long-term valuation, you may find it useful to review the detailed financial metrics on ValueRay.

Headlines to Watch Out For
  • Advanced wound care product sales drive revenue growth
  • Reimbursement policies impact product adoption and profitability
  • Clinical trial outcomes for pipeline products influence future value
  • Competition from alternative wound care therapies affects market share
Piotroski VR‑10 (Strict) 5.5
Net Income: 37.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.04 > 0.02 and ΔFCF/TA -4.92 > 1.0
NWC/Revenue: 46.47% < 20% (prev 43.25%; Δ 3.22% < -1%)
CFO/TA -0.02 > 3% & CFO -10.3m > Net Income 37.0m
Net Debt (39.2m) to EBITDA (77.4m): 0.51 < 3
Current Ratio: 3.62 > 1.5 & < 3
Outstanding Shares: last quarter (132.2m) vs 12m ago 0.03% < -2%
Gross Margin: 74.37% > 18% (prev 0.76%; Δ 7.36k% > 0.5%)
Asset Turnover: 102.9% > 50% (prev 96.82%; Δ 6.03% > 0%)
Interest Coverage Ratio: 24.82 > 6 (EBITDA TTM 77.4m / Interest Expense TTM 2.28m)
Altman Z'' 3.53
A: 0.44 (Total Current Assets 362.2m - Total Current Liabilities 100.1m) / Total Assets 598.7m
B: -0.01 (Retained Earnings -3.08m / Total Assets 598.7m)
C: 0.10 (EBIT TTM 56.6m / Avg Total Assets 548.3m)
D: -0.02 (Book Value of Equity -3.06m / Total Liabilities 164.8m)
Altman-Z'' Score: 3.53 = A
Beneish M -2.38
DSRI: 1.69 (Receivables 217.5m/109.9m, Revenue 563.9m/482.0m)
GMI: 1.02 (GM 74.37% / 75.99%)
AQI: 0.75 (AQ_t 0.13 / AQ_t-1 0.17)
SGI: 1.17 (Revenue 563.9m / 482.0m)
TATA: 0.08 (NI 37.0m - CFO -10.3m) / TA 598.7m)
Beneish M-Score: -2.38 (Cap -4..+1) = BBB
What is the price of ORGO shares? As of April 08, 2026, the stock is trading at USD 2.26 with a total of 18,280,449 shares traded.
Over the past week, the price has changed by -4.64%, over one month by -18.12%, over three months by -47.44% and over the past year by -41.90%.
Is ORGO a buy, sell or hold? Organogenesis Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ORGO.
  • StrongBuy: 3
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ORGO price?
Analysts Target Price 8 254%
Organogenesis Holdings (ORGO) - Fundamental Data Overview as of 08 April 2026
P/E Trailing = 14.9333
P/E Forward = 12.6743
P/S = 0.5108
P/B = 0.9644
Revenue TTM = 563.9m USD
EBIT TTM = 56.6m USD
EBITDA TTM = 77.4m USD
Long Term Debt = 82.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 132.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.2m USD (from netDebt column, last quarter)
Enterprise Value = 327.3m USD (288.2m + Debt 132.8m - CCE 93.7m)
Interest Coverage Ratio = 24.82 (Ebit TTM 56.6m / Interest Expense TTM 2.28m)
EV/FCF = -13.38x (Enterprise Value 327.3m / FCF TTM -24.5m)
FCF Yield = -7.47% (FCF TTM -24.5m / Enterprise Value 327.3m)
FCF Margin = -4.34% (FCF TTM -24.5m / Revenue TTM 563.9m)
Net Margin = 6.57% (Net Income TTM 37.0m / Revenue TTM 563.9m)
Gross Margin = 74.37% ((Revenue TTM 563.9m - Cost of Revenue TTM 144.5m) / Revenue TTM)
Gross Margin QoQ = 74.77% (prev 75.97%)
Tobins Q-Ratio = 0.55 (Enterprise Value 327.3m / Total Assets 598.7m)
Interest Expense / Debt = 0.18% (Interest Expense 236k / Debt 132.8m)
Taxrate = 31.10% (19.7m / 63.4m)
NOPAT = 39.0m (EBIT 56.6m * (1 - 31.10%))
Current Ratio = 3.62 (Total Current Assets 362.2m / Total Current Liabilities 100.1m)
Debt / Equity = 0.31 (Debt 132.8m / totalStockholderEquity, last quarter 433.9m)
Debt / EBITDA = 0.51 (Net Debt 39.2m / EBITDA 77.4m)
 Debt / FCF = -1.60 (negative FCF - burning cash) (Net Debt 39.2m / FCF TTM -24.5m)
 Total Stockholder Equity = 387.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.75% (Net Income 37.0m / Total Assets 598.7m)
RoE = 9.56% (Net Income TTM 37.0m / Total Stockholder Equity 387.3m)
RoCE = 12.06% (EBIT 56.6m / Capital Employed (Equity 387.3m + L.T.Debt 82.1m))
RoIC = 15.13% (NOPAT 39.0m / Invested Capital 257.9m)
WACC = 6.94% (E(288.2m)/V(421.0m) * Re(10.09%) + D(132.8m)/V(421.0m) * Rd(0.18%) * (1-Tc(0.31)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.13%
 [DCF] Fair Price = unknown (Cash Flow -24.5m)
 EPS Correlation: 15.66 | EPS CAGR: -8.58% | SUE: 0.84 | # QB: 2
Revenue Correlation: 40.76 | Revenue CAGR: 25.20% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-06-30): EPS=-0.09 | Chg7d=+0.000 | Chg30d=-0.080 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.17 | Chg7d=+0.000 | Chg30d=-0.340 | Revisions Net=-1 | Growth EPS=-140.1% | Growth Revenue=-28.9%
EPS next Year (2027-12-31): EPS=0.29 | Chg7d=+0.000 | Chg30d=-0.070 | Revisions Net=-1 | Growth EPS=+270.6% | Growth Revenue=+26.3%
External Resources
Dataroma Stockcircle